 Multimodality cisplatin treatment nonresectable alpha-fetoprotein-positive hepatoma Twenty-eight patients alpha-fetoprotein-positive AFP+ nonresectable hepatoma new multimodality Phase II program Induction therapy intravenous cisplatin cGy irradiation tumor volume fractions days Hepatic arterial infusion cisplatin IA-CDDP monthly intervals patients induction cycles IA-CDDP Twelve-month cumulative survival patients patients induction IA-CDDP Median survival Response rate complete partial overall patients treatment improved survival present series patients minimal hematologic toxicity possible integration new modalities therapy